Physician profile

Amanda Dove

Family Medicine · Rogersville, TN

NPI 1093978330

$9,428.78

in general payments reported to CMS, 2019-2025

46 companies · $953 in 2025

The $953 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,347.03

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $1,787.39 2019-2025 Ozempic, Rybelsus, Wegovy
Astrazeneca Pharmaceuticals LP $1,048.58 2019-2025 Farxiga, Breztri, Airsupra
Pfizer INC. $622.96 2019-2025
Abbvie INC. $621.38 2021-2025 Vraylar, Ubrelvy
Glaxosmithkline, LLC. $595.18 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Lilly USA, LLC $406.67 2019-2025 Mounjaro, Zepbound, Jardiance
Amgen INC. $390.55 2019-2025 Evenity, Repatha, Otezla
Takeda Pharmaceuticals U.S.A., INC. $375.82 2019-2025 Trintellix
Bayer Healthcare Pharmaceuticals INC. $357.71 2019-2025
Allergan, INC. $334.41 2019-2020
Janssen Pharmaceuticals, INC $324.99 2019-2024 Xarelto
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $290.40 2019-2025 Xifaxan
E.R. Squibb & Sons, L.L.C. $257.29 2021-2025 Eliquis, Camzyos
Amarin Pharma, INC. $255.46 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $184.15 2019-2022
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $162.25 2022-2023
Esperion Therapeutics, INC. $141.35 2020-2021
Sanofi-Aventis U.S. LLC $139.68 2019-2023
Merck Sharp & Dohme LLC $131.63 2019-2023 Verquvo, Belsomra, Steglatro
Phathom Pharmaceuticals, INC. $114.37 2024-2025 Voquezna
Xeris Pharmaceuticals, INC. $94.19 2020-2024 Gvoke Hypopen
Ironwood Pharmaceuticals, INC $83.52 2020-2023 Linzess
Idorsia Pharmaceuticals US INC $83.32 2023-2024 Quviviq
Inogen, INC. $77.39 2022-2025
Biohaven Pharmaceuticals, INC. $66.95 2020-2021
Axsome Therapeutics, INC. $42.86 2025 Auvelity
Upsher-Smith Laboratories LLC $39.30 2020
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $39.30 2024 Caplyta
Biohaven Pharmaceutical Holding Company LTD. $33.54 2022
Eisai INC. $33.13 2020
Kowa Pharmaceuticals America, INC. $27.63 2019-2020
Regeneron Healthcare Solutions, INC. $25.11 2022
Lundbeck LLC $21.87 2024 Rexulti
Dexcom, INC. $21.82 2024 Dexcom G6 Transmitter
Sumitomo Pharma America, INC. $21.38 2025 Gemtesa
Astellas Pharma US INC $18.90 2025 Veozah
Aimmune Therapeutics, INC. $18.60 2025 Zenpep
Exact Sciences Corporation $18.51 2025 The Cologuard Plus Collection Kit
Paratek Pharmaceuticals, INC. $17.27 2024 Nuzyra
Mayne Pharma Commercial LLC $17.23 2022
Alexion Pharmaceuticals, INC. $16.63 2020
Ortho Dermatologics, A Division of Bausch Health US, LLC $16.26 2019
Nestle Healthcare Nutrition INC. $14.93 2022
Impel Pharmaceuticals INC. $13.20 2022
Mylan Specialty L.P. $12.52 2020
Daiichi Sankyo INC. $11.20 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amanda Dove

$9,428.78

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $953 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/95343/amanda-dove

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.